Search Results - "Otterson, Gregory A."

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers by Ready, Neal, Hellmann, Matthew D, Awad, Mark M, Otterson, Gregory A, Gutierrez, Martin, Gainor, Justin F, Borghaei, Hossein, Jolivet, Jacques, Horn, Leora, Mates, Mihaela, Brahmer, Julie, Rabinowitz, Ian, Reddy, Pavan S, Chesney, Jason, Orcutt, James, Spigel, David R, Reck, Martin, O'Byrne, Kenneth John, Paz-Ares, Luis, Hu, Wenhua, Zerba, Kim, Li, Xuemei, Lestini, Brian, Geese, William J, Szustakowski, Joseph D, Green, George, Chang, Han, Ramalingam, Suresh S

“…CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of…”
Get full text

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis by Abu-Sbeih, Hamzah, Ali, Faisal S, Naqash, Abdul Rafeh, Owen, Dwight H, Patel, Sandipkumar, Otterson, Gregory A, Kendra, Kari, Ricciuti, Biagio, Chiari, Rita, De Giglio, Andrea, Sleiman, Joseph, Funchain, Pauline, Wills, Beatriz, Zhang, Jiajia, Naidoo, Jarushka, Philpott, Jessica, Gao, Jianjun, Subudhi, Sumit K, Wang, Yinghong

“…Immune checkpoint inhibitor (ICI) therapy often is suspended because of immune-mediated diarrhea and colitis (IMDC). We examined the rate of and risk factors…”
Get full text

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration by Drilon, Alexander, Clark, Jeffrey W., Weiss, Jared, Ou, Sai-Hong Ignatius, Camidge, D. Ross, Solomon, Benjamin J., Otterson, Gregory A., Villaruz, Liza C., Riely, Gregory J., Heist, Rebecca S., Awad, Mark M., Shapiro, Geoffrey I., Satouchi, Miyako, Hida, Toyoaki, Hayashi, Hidetoshi, Murphy, Danielle A., Wang, Sherry C., Li, Sherry, Usari, Tiziana, Wilner, Keith D., Paik, Paul K.

“…MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs) 1 . These alterations are associated with increased MET activity and…”
Get full text

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial by Herbst, Roy S, Dr, Ansari, Rafat, MD, Bustin, Frederique, MD, Flynn, Patrick, MD, Hart, Lowell, MD, Otterson, Gregory A, MD, Vlahovic, Gordana, MD, Soh, Chang-Heok, PhD, O'Connor, Paula, MD, Hainsworth, John, MD

“…Summary Background Bevacizumab and erlotinib target different tumour growth pathways with little overlap in their toxic-effect profiles. On the basis of…”
Get full text

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients by Chabon, Jacob J., Simmons, Andrew D., Lovejoy, Alexander F., Esfahani, Mohammad S., Newman, Aaron M., Haringsma, Henry J., Kurtz, David M., Stehr, Henning, Scherer, Florian, Karlovich, Chris A., Harding, Thomas C., Durkin, Kathleen A., Otterson, Gregory A., Purcell, W. Thomas, Camidge, D. Ross, Goldman, Jonathan W., Sequist, Lecia V., Piotrowska, Zofia, Wakelee, Heather A., Neal, Joel W., Alizadeh, Ash A., Diehn, Maximilian

“…Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in…”
Get full text

Molecular pathways and therapeutic targets in lung cancer by Shtivelman, Emma, Hensing, Thomas, Simon, George R, Dennis, Phillip A, Otterson, Gregory A, Bueno, Raphael, Salgia, Ravi

“…Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the…”
Get full text

Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma by Owen, Dwight, Chu, Benjamin, Lehman, Amy M, Annamalai, Lakshmanan, Yearley, Jennifer H, Shilo, Konstantin, Otterson, Gregory A

“…Thymic epithelial tumors (TETs) including thymoma and thymic carcinoma are rare tumors with little data available to guide treatment. Immunotherapy with…”
Get more information

Agents to treat BRAF- mutant lung cancer by Alvarez, Jean G Bustamante, Otterson, Gregory A

“…mutations are seen in up to 3.5-4% of the non-small cell lung cancer (NSCLC) patients. mutations account for 50% of these cases, and the remaining mutations…”
Get full text

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications by Spakowicz, Daniel, Hoyd, Rebecca, Muniak, Mitchell, Husain, Marium, Bassett, James S, Wang, Lei, Tinoco, Gabriel, Patel, Sandip H, Burkart, Jarred, Miah, Abdul, Li, Mingjia, Johns, Andrew, Grogan, Madison, Carbone, David P, Verschraegen, Claire F, Kendra, Kari L, Otterson, Gregory A, Li, Lang, Presley, Carolyn J, Owen, Dwight H

“…The microbiome has been shown to affect the response to Immune Checkpoint Inhibitors (ICIs) in a small number of cancers and in preclinical models. Here, we…”
Get full text

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC by Drilon, Alexander, Chiu, Chao-Hua, Fan, Yun, Cho, Byoung Chul, Lu, Shun, Ahn, Myung-Ju, Krebs, Matthew G., Liu, Stephen V., John, Thomas, Otterson, Gregory A., Tan, Daniel S.W., Patil, Tejas, Dziadziuszko, Rafal, Massarelli, Erminia, Seto, Takashi, Doebele, Robert C., Pitcher, Bethany, Kurtsikidze, Nino, Heinzmann, Sebastian, Siena, Salvatore

“…Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001,…”
Get full text

Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival by Miah, Abdul, Tinoco, Gabriel, Zhao, Songzhu, Wei, Lai, Johns, Andrew, Patel, Sandip, Li, Mingjia, Grogan, Madison, Lopez, Gabrielle, Husain, Marium, Hoyd, Rebecca, Mumtaz, Khalid, Meara, Alexa, Bertino, Erin M., Kendra, Kari, Spakowicz, Daniel, Otterson, Gregory A., Presley, Carolyn J., Owen, Dwight H.

“…Purpose Immune checkpoint inhibitors (ICIs) are associated with a unique set of immune-related adverse events (irAEs). Few studies have evaluated the risk…”
Get full text

A novel classification of lung cancer into molecular subtypes by West, Lisandra, Vidwans, Smruti J, Campbell, Nicholas P, Shrager, Jeff, Simon, George R, Bueno, Raphael, Dennis, Phillip A, Otterson, Gregory A, Salgia, Ravi

“…The remarkably heterogeneous nature of lung cancer has become more apparent over the last decade. In general, advanced lung cancer is an aggressive malignancy…”
Get full text

MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer by Crawford, Melissa, Batte, Kara, Yu, Lianbo, Wu, Xin, Nuovo, Gerard J., Marsh, Clay B., Otterson, Gregory A., Nana-Sinkam, Serge P.

“…Lung cancer is the most frequent cause of cancer-related death in this country for men and women. MicroRNAs (miRNAs) are a family of small non-coding RNAs…”
Get full text

Smoking status and survival in the national comprehensive cancer network non–small cell lung cancer cohort by Ferketich, Amy K., Niland, Joyce C., Mamet, Rizvan, Zornosa, Carrie, D'Amico, Thomas A., Ettinger, David S., Kalemkerian, Gregory P., Pisters, Katherine M., Reid, Mary E., Otterson, Gregory A.

“…BACKGROUND: The objectives of this study were to evaluate survival among current smokers, former smokers, and never smokers who are diagnosed with non–small…”
Get full text

A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer by Bertino, Erin M, McMichael, Elizabeth L, Mo, Xiaokui, Trikha, Prashant, Davis, Melanie, Paul, Bonnie, Grever, Michael, Carson, William E, Otterson, Gregory A

“…mAbs can induce antibody-dependent cellular cytotoxicity (ADCC) via the innate immune system's ability to recognize mAb-coated cancer cells and activate immune…”
Get full text

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib‐Responsive Non‐Small Cell Lung Cancer by Halmos, Balazs, Pennell, Nathan A., Fu, Pingfu, Saad, Shumaila, Gadgeel, Shirish, Otterson, Gregory A., Mekhail, Tarek, Snell, Michael, Kuebler, J. Philip, Sharma, Neelesh, Dowlati, Afshin

“…Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy is clearly beneficial in patients with advanced EGFR‐mutated…”
Get full text

Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107) by Jahan, Thierry, Gu, Lin, Kratzke, Robert, Dudek, Arkadiusz, Otterson, Gregory A, Wang, Xiaofei, Green, Mark, Vokes, Everett E, Kindler, Hedy Lee

“…Abstract Introduction The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the efficacy and safety of vatalanib in…”
Get full text

Immunotherapy in inoperable stage III non-small cell lung cancer: a review by Jain, Natasha A, Otterson, Gregory A

“…The leading cause of cancer-related deaths in the United States continues to be lung cancer. Approximately 25-30% of patients are diagnosed with locally…”
Get full text

Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report by Sheel, Ankur, Bae, Junu, Asada, Ashlee, Otterson, Gregory A, Baliga, Ragavendra R, Koenig, Kristin L

“…Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic…”
Get full text

Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database by Miller, Eric D, Fisher, James L, Haglund, Karl E, Grecula, John C, Xu-Welliver, Meng, Bertino, Erin M, He, Kai, Shields, Peter G, Carbone, David P, Williams, Terence M, Otterson, Gregory A, Bazan, Jose G

“…To compare patterns of care for elderly patients versus non-elderly patients with non-surgically treated stage III non-small cell lung cancer (NSCLC) using the…”
Get full text